LSE-listed Avacta Therapeutics, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumour payloads directly to the tumour, has agreed the sale of in vitro diagnostics…
UK: Avacta agrees sale of Launch Diagnostics to Palex
…
…






